Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome Patients were randomly assigned to ...
The role of IPSS-m in predicting survival and relapse after allogeneic HSCT for MDS: A single center experience.
The VERONA trial showed no significant overall survival improvement with Venclexta plus azacitidine in intermediate/high-risk MDS patients compared to placebo. The combination arm demonstrated higher ...
Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...
Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results